Aicardi-Goutieres syndrome …

Developmental Malformations

Updated 03.22.2024
Released 07.13.1999
Expires For CME 03.22.2027

Aicardi-Goutieres syndrome

Authors: Kapil Arya MD, Ezgi Saylam MD

See Contributor Disclosures

Editor: Ganeshwaran H Mochida MD

Aicardi-Goutieres syndrome

In This Article

Quick Link

Introduction

Overview

Aicardi-Goutieres syndrome is a genetically heterogeneous multisystemic disorder due to defects in processing nucleic acids, often leading to progressive encephalopathy and cutaneous, hematological, and neurodevelopmental problems. Initially recognized as an early-onset leukoencephalopathy with intracranial calcifications, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia in the infancy period resembling a congenital infection, Aicardi-Goutieres syndrome is now recognized as a multisystem disorder with a highly variable disease progression and morbidity. Molecular studies have established at least nine genes that encode enzymes causative of Aicardi-Goutieres syndrome: TREX1 (3’ repair exonuclease 1), RNASEH2A (ribonuclease H2 subunit A), RNASEH2B, RNASEH2C, SAMHD1 (SAM-domain- and HD domain-containing protein 1), ADAR1 (adenosine deaminase acting on RNA 1), IFIH1 (interferon induced with helicase C domain 1), LSM11, and RNU71. Whereas IFIH1 is inherited in an autosomal dominant pattern, other genes are inherited in an autosomal recessive pattern, except specific variants in TREX1 and ADAR.

Key points

	• Aicardi-Goutieres syndrome is a genetically heterogenous multisystemic disorder with a variable onset and phenotype.
	• Subacute-onset encephalopathy, loss of motor and cognitive skills, paraparesis, epileptic seizures, microcephaly, dystonia, and non-neurologic manifestations, such as chilblain-like skin lesions, glaucoma, abnormal dentition, hypothyroidism, lupus-like disease, and arthropathy, can be seen in patients with Aicardi-Goutieres syndrome.
	• Syndrome manifestations include hepatosplenomegaly, elevated liver enzymes, thrombocytopenia, sterile pyrexias, and basal ganglia calcifications. Therefore, Aicardi-Goutieres syndrome can mimic intrauterine TORCH infections and congenital HIV, both clinically and radiologically, in the absence of evidence of infection.
	• Cerebrospinal fluid analysis reveals pleocytosis, suggesting a possible inflammatory reaction.
	• Molecular genetic analysis and the establishment of causative genes (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, IFIH1, LSM11, RNU71) that encode proteins in nucleic acid metabolism have marked an era in the pathogenesis and classification of clinical phenotypes.
	• The identification of the molecular basis and subsequent progress in understanding disease pathogenesis have led to the first attempts in treatment, and further rationales for treatment modalities are expected to become available in the near future.

Historical note and terminology

In 1984, Jean Aicardi and Francoise Goutieres described eight children from five families presenting with early-onset encephalopathy characterized by basal ganglia calcifications, white matter abnormalities, cerebral atrophy, and CSF lymphocytosis (02). During the first year of life, spasticity, dystonia, and microcephaly were reported in these children. The consanguinity in families and recurrence of this clinical picture in siblings suggested a genetic basis for this phenotype, with an autosomal recessive trait. The authors identified nine previously reported, possibly similar cases of unclassified leukodystrophy in the literature that may have been the same clinical entity.

In 1988, Pierre Lebon identified the additional feature of this disease: elevation of CSF interferon alfa concentrations in the absence of demonstrable infection. This finding was a valuable marker in clinical diagnosis, and it also supported Aicardi and Goutieres’s suggestion that Aicardi-Goutieres syndrome was an inflammatory disease. Following publication by Aicardi and Goutieres, similar cases were subsequently reported (35; 34; 20; 26; 21; 22; 28). The term “congenital infection–like syndrome” was used, cutaneous features were described, and autoimmune disease features were noted.

The disorder was listed as “Aicardi-Goutieres syndrome” in 1992, and new cases were added to the disorder in the following years. There were probably many more cases of this early-onset hereditary encephalopathy characterized by microcephaly, leukodystrophy, diffuse cerebral atrophy, CSF lymphocytosis, and increased CSF levels of interferon alfa that were unrecognized. The phenotypic overlap of Aicardi-Goutieres syndrome with pseudo-TORCH syndrome was noted (07).

In 2005, Crow and colleagues hypothesized that abnormal regulation of interferon alfa causes the phenotypic similarities shared by systemic lupus erythematosus, congenital rubella, in utero HIV infection, and Aicardi-Goutieres syndrome. They emphasized that the identification and characterization of the Aicardi-Goutieres syndrome gene may provide new insights into the control of interferon alfa production and the disease pathogenesis (06).

Cree encephalitis, an early-onset progressive encephalopathy in Cree indigenous families in Canada (03), was originally considered a separate disorder, but subsequent genetic analysis revealed that it is the same as Aicardi-Goutieres syndrome 1 (08).

Dale and colleagues noted a congenital infection–like syndrome with clinical features similar to systemic lupus erythematosus (15). They described the disease as “familial systemic lupus erythematosus” and highlighted phenotypic similarities with Aicardi-Goutieres syndrome.

With the identification of the genetic basis of Aicardi-Goutieres syndrome, clinical phenotypes have been remarkably expanded. Mutations in the TREX1 (AGS1), RNASEH2A (AGS4), RNASEH2B (AGS2), RNASEH2C (AGS3), SAMHD1 (AGS5), ADAR1 (AGS6), and IFIH1 (AGS7) genes have been described as disease-causing mutations. Crow and colleagues suggested the term “type 1 interferonopathy” as the disease has various types of clinical manifestations, including neurologic and non-neurologic symptoms. In 2020, two new genes were described as a cause of disease. The LSM11 gene (AGS8) was described in two brothers, born of first-cousin parents, with Aicardi-Goutieres syndrome who died at 2 years of age. The RNU71 gene was described in 16 patients from 11 families with Aicardi-Goutieres syndrome with an autosomal recessive inheritance (28; 36).

Clinical manifestations

Presentation and course

Aicardi-Goutieres syndrome is a genetically heterogeneous disease typically characterized by encephalopathy or intellectual disability, microcephaly during the first year, psychomotor delay, dystonia, spasticity, sterile pyrexias, hepatosplenomegaly, and chilblain lesions. Some affected children display features at birth, but most infants with Aicardi-Goutieres syndrome seem to have disease manifestations in the first 12 months after birth. Clinical observations suggest the presence of an early period of active regression occurring for several months, followed by a stable disease course with stable encephalopathy (13).

Various clinical phenotypes with different mutations have been reported. Crow and colleagues published a paper that summarized the disease, with Aicardi-Goutieres syndrome–related genes and clinical phenotypes. This article uses the same classification as it is a clinically applicable and basic classification (23).

Clinical phenotypes

Prenatal and infantile–onset Aicardi-Goutieres syndrome. Affected infants present with microcephaly, feeding problems, jitteriness, abnormal movements, and epileptic disorders. Hematologic disturbances, such as anemia, thrombocytopenia, and elevated liver function tests with hepatomegaly, can be seen and remarkably mimic a transplacentally acquired infection (“pseudo-TORCH”). The onset of disease is considered to be in utero or infantile. Affected infants demonstrate clinical features at birth or abrupt-onset crying, irritability, excessive startle, and eye movement abnormalities. Progressive loss of acquired skills may be noted a few months after birth. Encephalopathy lasts for a few months and is associated with developmental delay, neurologic regression, and microcephaly. Although TREX1 mutations are most commonly associated with in utero onset, and RNASEH2B gene mutations are frequently associated with infantile onset, many Aicardi-Goutieres syndrome–related mutations (AGS1-7) can result in this clinical phenotype. This phenotype is associated with an increased mortality rate in infancy. Neuroimaging findings with intracranial calcifications, frontotemporal white matter abnormalities, leukodystrophy, and cerebral atrophy are valuable for the diagnosis (23).

Later-onset Aicardi-Goutieres syndrome. Later-onset Aicardi-Goutieres syndrome begins after the first year of life with subacute encephalopathy and neurologic regression and demonstrates similar clinical findings and neuroimaging markers. Orcesi and colleagues described a case who was healthy until the age of 16 months, when she developed hypersomnia, irritability, and high-grade fever (25). Infectious work-up was unremarkable, including TORCH panel. Neurologic exam revealed axial hypotonia with pyramidal signs and loss of all milestones within 3 weeks. MRI brain showed bilateral lentiform nucleus calcifications. CSF demonstrated raised levels of interferon alfa, and genetic analysis revealed an AGS2/RNASEH2B gene mutation. At 32 months of age, neurologic exam showed truncal and neck hypotonia as well as pyramidal and extrapyramidal signs. There was no recovery of previously acquired milestones. Similar cases of RNASEH2B and ADAR1 gene mutations have been reported in the literature.

Bilateral striatal necrosis. Dystonia is the key element of this clinical picture. Patients may also present with developmental delay, neurologic regression, eye movement abnormalities, spastic paraparesis, and autoimmune features similar to the classic Aicardi-Goutieres syndrome phenotype. Neuroimaging demonstrates bilateral striatal necrosis. ADAR1 gene mutations represent an important cause of bilateral striatal necrosis. Onset of the disease can be early or later in life. The clinical course can be severe, with progressive dystonia and early death. ADAR1-related disease should be considered in any child with bilateral striatal necrosis or unexplained subacute onset dystonia (23).

Hereditary spastic paraparesis. Patients with slowly progressive (“nonsyndromic”) spastic paraparesis due to mutations in ADAR1, RNASEH2B, and IFIH1 have been reported in recent years. According to the literature, cranial and spinal cord imaging can be completely normal, or only nonspecific findings may be seen. Spastic paraparesis can be slowly progressive over the years (23). A dominant variant in the ADAR gene (c.3019G> A) was specifically associated with neurologic manifestations that mimic spastic paraplegia and dystonic cerebral palsy (11).

SAMHD1-related cerebrovascular disease. A particular feature of this phenotype is intracerebral large-vessel disease, including aneurysms, moyamoya disease, intracranial stenosis with infarcts, and intracerebral hemorrhage, which is frequently associated with biallelic pathogenic variants in the SAMHD1 gene. Mutations in this gene can be associated with clinically heterogeneous phenotypes, including classic Aicardi-Goutieres syndrome or cerebrovasculopathy, with normal intellectual function (27). Some case studies suggest that non-neurologic features, such as glaucoma and skin disease, are generally present with this genotype (23). Although intracerebral large artery involvement has been a particular feature of SAMHD1-associated disease, similar pathology has also been described with the homozygous TREX1 variant (38).

Epileptic seizures occur in approximately one quarter of patients with Aicardi-Goutieres syndrome, and the electroclinical basis still requires further studies. Electroencephalography may show a diffuse background slowing and disruption of electrical organization (16).

Non-neurologic features. It is important to recognize non-neurologic features of the disease as a clue in diagnosis. Chilblains, glaucoma, sterile pyrexias, deforming arthropathy, and some autoimmune features, including lupus-like disease and thyroiditis, can be seen.

Aicardi-Goutieres syndrome was initially considered a progressive neurodegenerative disease. However, with the identification of more cases and genes, it is now thought that the disease does not progress beyond the encephalopathic period in most cases. The disease generally has a “plateau” period after the neurologic regression episode with encephalopathy in the classic presentation.

Table 1. Summary of Clinical Manifestations in Aicardi-Goutieres Syndrome

Clinical evaluation
Systems	Symptoms	Workup or specific features
Cardiac	• Cardiac valve calcification (IFIH1 and ADAR) • Infantile-onset cardiomyopathy (TREX1)
Cutaneous	• Acrocyanosis • Nail abnormalities • Panniculitis • Periungal erythema / necrotic lesions of fingers and outer helix • Recurrent oral lesions • Vasculopathic skin lesions (chilblain lesions)	• Angiokeratoma observed in IFIH1 • Dyschromatosis symmetrica hereditaria: ADAR1 • Familial chilblain lupus: TREX1 and SAMHD1 • Lesional biopsy of chilblains: basal vacuolar degeneration, interface dermatitis, dermal infiltrate • Mouth ulcers most frequently found in SAMHD1 mutations • Psoriasis described in IFIH1 mutation
Endocrinopathies	• Adrenal insufficiency • Central diabetes insipidus • Diabetes mellitus • Growth hormone deficiency • Hypothyroidism
Hematologic	• Autoimmune cytopenias • Thrombocytopenia in the neonatal period mimicking congenital infection
Hepatic	• Autoimmune hepatitis • Hepatomegaly • Transaminitis	• Presence of liver specific antibodies
Musculoskeletal	• Joint contractures • Lupus like arthritis • Myopathy • Progressive arthropathy
Neurologic	• Acute / subacute neurologic decline • Dystonia • Focal motor deficits • Global developmental delay • Irritability • Progressive microcephaly encephalopathy	• Basal ganglia or other intracerebral calcifications • Bilateral striatal necrosis: ADAR1 • Cerebral atrophy • CSF: sterile CSF pleocytosis, elevated neopterin, and IFN-alpha • Deep white matter cysts, frequently associated with TREX1 • Intracerebral large vessel vasculitis/ moyamoya • Porencephalic cysts: RNASEH2B
Ophthalmologic	• Glaucoma • Retinopathy
Respiratory	• Pulmonary hypertension
(04; 17)

Prognosis and complications

The classic clinical course of the disease is a period of encephalopathy, loss of acquired milestones, and neurologic regression with progressive radiological changes. Clear progression has been noted in some types of ADAR1 mutations. The disease generally has a “plateau phase” after the initial regression; however, profound disabilities do not improve. Early death occurs in childhood in some patients (approximately 20%); however, most patients (approximately 70% to 75%) survive after the initial regression episode without further deterioration (10).

Mortality is considered to be correlated with genotype. RNASEH2B mutations were associated with later age at presentation and lower mortality when compared to individuals with RNASEH2A, RNASEH2C, and TREX1 mutations (29). LSM11 was reported in two siblings who presented with neonatal irritability, seizures, and developmental delay who died at 2 years of age. The RNU71 gene was described in 16 patients who presented with increased tone in the neonatal period, spastic dystonia, and diplegia or quadriplegia. Early deaths were noted in five patients due to different reasons (kidney failure, liver failure, seizure). Clinical prognosis and presentation vary between patients (36).

Increasing knowledge of the molecular basis of the disease mechanism has led to novel targeted therapies. Multicenter studies are needed on the efficacy of novel treatments and the potential outcome of the disease (17).

Biological basis

The identification of the genetic basis of Aicardi-Goutieres syndrome has marked an era of understanding of the clinical phenotypes and disease pathogenesis. The first gene mutation to be revealed was TREX1, which was described in 2006 in 10 families (09). Mutation screening in patients from 127 pedigrees with a clinical diagnosis revealed RNASEH2A, RNASEH2B, and RNASEH2C mutations, in addition to TREX1 mutations (29). Subsequent analysis revealed SAMHD1, ADAR2, and IFIH1 mutations, which broadened the clinical phenotypes. LSM11 and RNU71 gene mutations were described in 2020 in patients with a classic presentation of Aicardi-Goutieres syndrome (36).

Etiology and pathogenesis

Mutations in Aicardi-Goutieres syndrome–related genes account for most of the patients with classic Aicardi-Goutieres syndrome. It has been reported that these genes encode specific proteins involved in the metabolism of DNA or RNA. Mutations in these genes result in the accumulation of endogenous nucleic acids and are recognized as viral or nonself, which initiates the induction of type 1 interferon-related immune response (13). Interestingly, elevated CSF levels of interferon alfa are a diagnostic parameter for Aicardi-Goutieres syndrome. Furthermore, the presence of clinical overlaps between systemic lupus erythematosus and Aicardi-Goutieres syndrome has been well recognized. Therefore, the term “type 1 interferonopathy” is recommended to describe the wider spectrum of Aicardi-Goutieres syndrome, which is thought to be caused by the failure of self-versus-non-self recognition. It has been hypothesized that type 1 interferon is directly relevant to diagnosis. Mutations in these genes result in type 1 interferon response, which is similar to that after exposure to a virus and may explain the resemblance to a congenital infection. It was shown that type 1 interferon signaling dysregulation can happen in different mechanisms:

(1) Cytosolic accumulation of endogenous nucleic acids by loss-of-function mutations of genes that encode degradation

(2) Alterations in DNA-sensing and RNA-sensing pathways

(3) Activation of interferon signaling regulators

(4) Deactivation of negative interferon signaling regulators

(5) Proteasomal dysfunction causing increased interferon signaling (14)

In addition, many researchers have revealed the role of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway in autoimmune disorders, including Aicardi-Goutieres syndrome (19). It has a key role in the recognition of invasive pathogens.

It is essential to highlight the complex molecular heterogeneity of the disorder for underlying mechanisms as the field of targeted therapies is emerging. For example, RNase H2 has been shown to play a role in the transcription of genes by maintaining a critical R-loop homeostasis (05). The RNase H2 mutation interferes with transcription, causing accumulation of R loops and a displaced DNA strand that causes short and intronless genes. The accumulation of R-loops leads to activation of the immune system caused by the damaged DNA.

ADAR converts adenosine to inosine in dsDNA and stabilizes the DNA helix (32). It protects dsRNA from dsRNA sensing molecules and inhibits the interferon-mediated response.

SAMHD1 functions as a ssRNA 3’exonuclease, and mutations cause RNA accumulation in cells and dissolution of RNA-protein condensates, which then triggers the activation of type 1 interferon (24).

Phenotype	Inheritance	Gene/Locus
Aicardi-Goutieres syndrome 1, AGS1	autosomal dominant, autosomal recessive	TREX1
Aicardi-Goutieres syndrome 2, AGS2	autosomal recessive	RNASEH2B
Aicardi-Goutieres syndrome 3, AGS3	autosomal recessive	RNASEH2C
Aicardi-Goutieres syndrome 4, AGS4	autosomal recessive	RNASEH2A
Aicardi-Goutieres syndrome 5, AGS5	autosomal recessive	SAMHD1
Aicardi-Goutieres syndrome 6, AGS6	autosomal recessive	ADAR
Aicardi-Goutieres syndrome 7, AGS7	autosomal dominant	IFIH1
Aicardi-Goutieres syndrome 8, AGS8	autosomal recessive	LSM11
Aicardi-Goutieres syndrome 9, AGS9	autosomal recessive	RNU71

Differential diagnosis

Confusing conditions

The literature has highlighted the exclusion of the presence of other prenatal or perinatal infections, including TORCH infections, Zika virus, and HIV, in the differential diagnosis of Aicardi-Goutieres syndrome. Considering the early-onset encephalopathy with white matter abnormalities, it is necessary to exclude metabolic and neurodegenerative disorders.

The differential diagnosis of Aicardi-Goutieres syndrome includes the following:

	TORCH infections. With the various phenotypical and radiological overlaps, TORCH infections are the most common condition. Its exclusion is essential in guiding genetic counseling.
	Band-like calcification polymicrogyria. Affected patients demonstrate intracranial calcifications, microcephaly, seizures, and psychomotor delay, which mimic Aicardi-Goutieres syndrome. Polymicrogyria and pathogenic variants in OCLN differentiate this syndrome from Aicardi-Goutieres syndrome.
	MICS (microcephaly, intracranial calcification syndrome, pseudo-TORCH syndrome). This is a heterogeneous group of diseases that may mimic Aicardi-Goutieres syndrome.
	Mitochondrial cytopathies. Mitochondrial cytopathies, including Leigh syndrome, cause subacute-onset encephalopathy. Serum lactate and pyruvate levels are elevated.
	Endocrine diseases. Endocrine diseases, including hypoparathyroidism and pseudohypoparathyroidism; metabolic diseases, including biotinidase deficiency; and carbonic anhydrase II deficiency, can also cause intracranial calcifications.
	Cockayne syndrome and other leukodystrophies. Cockayne syndrome and other leukodystrophies, including Alexander disease, megalencephalic leukoencephalopathy with subcortical cysts, childhood ataxia with central nervous system hypomyelination/vanishing white matter disease, and Pelizaeus-Merzbacher disease, may have similar MRI findings with frontotemporal white matter changes.
	Neonatal lupus erythematosus. Basal ganglia calcifications and white matter changes have been reported.
	3-hydroxyisobutyric aciduria
	Leukoencephalopathy, brain calcifications, and cysts (Labrune syndrome)
	Cerebroretinal microangiopathy with calcifications and cysts

Diagnostic workup

Diagnostic workup should focus on raising early suspicion and on facilitating genetic testing and clinical and laboratory workup. Aicardi-Goutieres syndrome has characteristic clinical and radiological findings as well as supportive laboratory parameters. Aicardi-Goutieres syndrome should be considered in individuals with abrupt or subacute encephalopathy, acquired microcephaly, dystonia, sterile pyrexias, chilblain lesions, and characteristic neuroimaging findings. There has not been a standardized, validated tool that can measure symptom severity. However, the “Aicardi-Goutieres syndrome–specific neurologic scale,” which assesses gross motor, fine motor, speech, and cognitive skills as well as head circumference, seems to be a promising tool to longitudinally follow neurologic function in this population (01).

Neuroimaging demonstrates basal ganglia calcifications, which include the putamen, thalamus, and globus pallidus, in particular. White matter changes, particularly in frontotemporal regions, may include temporal lobe cyst formation. Progressive cerebral atrophy, cerebrovasculopathy, and intracranial stenosis are other findings.

Elevated liver enzymes, anemia, and thrombocytopenia are nonspecific but supportive laboratory findings for the diagnosis of Aicardi-Goutieres syndrome.

Increased expression of type 1 interferon-regulated genes (interferon signature) is a nonspecific finding in Aicardi-Goutieres syndrome and can be seen in any other autoimmune disease (29; 30; 12; 10). CSF analysis reveals chronic CSF pleocytosis, elevated interferon alfa activity, and raised neopterin levels.

Prompt and comprehensive genetic testing with next-generation sequencing is crucial to advancing potential targeted therapies. It is important to note that large deletions may be missed on exome sequencing.

The diagnosis is established in individuals with typical clinical findings, characteristic neuroimaging features, or the identification of pathogenic variants in Aicardi-Goutieres syndrome–related genes.

Management

Outcomes

There is no definitive cure for Aicardi-Goutieres syndrome. Current treatment options aim to prevent end organ damage by controlling inflammation and to improve quality of life. A multidisciplinary approach is recommended to optimize medical care in the setting of multisystemic involvement.

After the initial diagnosis and developmental assessment, the assessment of feeding and nutritional status is recommended to establish the extent of the disease. EEG can be performed to evaluate seizure-like activity, if clinically suspected. Given the hereditary nature of the disease, genetic counseling is essential. Anticipatory guidance and surveillance workup, including monitoring signs of diabetes insipidus in the neonatal period, glaucoma assessment in the first few years of life, assessment of the spine for the development of scoliosis, and monitoring signs of diabetes mellitus and hypothyroidism, are recommended.

There are currently therapies under investigation and ongoing research studies (13). Considering the inflammatory basis of the disease, immunosuppressive treatments have been investigated in a small number of individuals. In an open-label pilot study from France, eight patients with specific mutations were treated with reverse-transcriptase inhibitors over a period of 12 months (31). A reduction in interferon signaling and an increase in cerebral blood flow was reported in patients with Aicardi-Goutieres syndrome. A controlled trial with a larger group of patients is recommended.

Crow and colleagues reported definitive improvement in TREX1-related skin disease and IFIH1-related systemic inflammation. In 2020, another open-label study from a single center in the United States included 35 patients with genetically confirmed Aicardi-Goutieres syndrome (37). Patients received baricitinib, an oral JAK1 and JAK2 inhibitor, which resulted in some clinical improvement in some patients as well as changes in interferon signaling. Fremond and colleagues trialed JAK1/2 inhibition in 11 patients with Aicardi-Goutieres syndrome (18). A clear benefit of JAK1/2 inhibition was reported on certain systemic features of Aicardi-Goutieres syndrome over a follow-up period of 17 months. Only a limited benefit was reported on the neurologic symptoms of the disease, which the authors attribute to the late stage of the disease at treatment onset and poor CNS penetration of the drug. Glucocorticoids have been shown to decrease interferon levels in CSF, although empirical treatment with corticosteroids or immunoglobulin did not show any clear evidence of benefits (25).

Increasing knowledge of the biallelic SAMHD1 mutations related to intracranial large vessel disease raises questions about the management of arteriopathy. Given the lack of evidence, no definitive statement can currently be made, and each case should be evaluated individually.

References

01: Adang LA, Gavazzi F, Jawad AF, et al. Development of a neurologic severity scale for Aicardi Goutieres syndrome. Mol Genet Metab 2020;130(2):153-60. PMID 32279991
02: Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984;15(1):49-54. PMID 6712192
03: Black DN, Waters GV, Andermann E, et al. Encephalitis among Cree children in northern Quebec. Ann Neurol 1988;24(4):483-9. PMID 3239950
04: Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis 2022;81(5):601-13. PMID 35086813
05: Cristini A, Tellier M, Constantinescu F, et al. RNase H2, mutated in Aicardi-Goutières syndrome, resolves co-transcriptional R-loops to prevent DNA breaks and inflammation. Nat Commun 2022;13(1):2961. PMID 35618715
06: Crow YJ, Adam MP, Ardinger HH. Aicardi-Goutieres syndrome. In: GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle. Accessed 2022. PMID 20301648
07: Crow YJ, Black DN, Ali M, et al. Cree encephalitis is allelic with Aicardi-Goutieres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J Med Genet 2003;40(3):183-7. PMID 12624136
08: Crow YJ, Jackson AP, Roberts E, et al. Aicardi-Goutieres syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am J Hum Genet 2000;67(1):213-21. PMID 10827106
09: Crow YJ, Leitch A, Hayward BE, et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 2006;38(8):910-6. PMID 16845400
10: Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol 2015;15(7):429-40. PMID 26052098
11: Crow YJ, Marshall H, Rice GI, et al. Leukoencephalopathy with calcifications and cysts: genetic and phenotypic spectrum. Am J Med Genet A 2021;185(1):15-25. PMID 33029936
12: Crow YJ, Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet 2009;18(R2):R130-6. PMID 19808788
13: Crow YJ, Shetty J, Livingston JH. Treatments in Aicardi-Goutieres syndrome. Dev Med Child Neurol 2020;62(1):42-7. PMID 31175662
14: d'Angelo DM, Di Filippo P, Breda L, Chiarelli F. Type I interferonopathies in children: an overview. Front Pediatr 2021;9:631329. PMID 33869112
15: Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and congenital infection-like syndrome. Neuropediatrics 2020;31(3):155-8. PMID 10963105
16: De Giorgis V, Varesio C, Viri M, et al. The epileptology of Aicardi-Goutières syndrome: electro-clinical-radiological findings. Seizure 2021;86:197-209. PMID 33589296
17: Dell'Isola GB, Dini G, Culpepper KL, et al. Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome. World J Pediatr 2023;19(7):635-43. PMID 36650407
18: Fremond ML, Hully M, Fournier B, et al. JAK inhibition in Aicardi-Goutières syndrome: a monocentric multidisciplinary real-world approach study. J Clin Immunol 2023;43(6):1436-47. PMID 37171742
19: Hu Y, Chen B, Yang F, et al. Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: biologic function, mechanisms and clinical prospection. Autoimmun Rev 2022;21(9):103155. PMID 35902046
20: Kato M, Ishii R, Honma A, Ikeda H, Hayasaka K. Brainstem lesion in Aicardi-Goutieres syndrome. Pediatr Neurol 1998;19(2):145-7. PMID 9744637
21: Lanzi G, Fazzi E, D’Arrigo AD. Aicardi-Goutieres syndrome: a description of 21 new cases and a comparison with the literature. Eur J Paediatr Neurol 2002;6 Suppl A:A9-22. PMID 12365365
22: Lanzi G, Fazzi E, D’Arrigo D, et al. The natural history of Aicardi-Goutieres syndrome: follow-up of 11 Italian patients. Neurology 2005;64(9):1621-4. PMID 15883328
23: Livingston JH, Crow YJ. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutieres syndrome and beyond. Neuropediatrics 2016;47(6):355-60. PMID 27643693
24: Maharana S, Kretschmer S, Hunger S, et al. SAMHD1 controls innate immunity by regulating condensation of immunogenic self RNA. Mol Cell 2022;82(19):3712-28.e10. PMID 36150385
25: Orcesi S, Pessagno A, Biancheri R, et al. Aicardi-Goutières syndrome presenting atypically as a sub-acute leukoencephalopathy. Eur J Paediatr Neurol 2008;12(5):408-11. PMID 18069026
26: Ostergaard JR, Christensen T, Nehen AM. A distinct difference in clinical expression of two siblings with Aicardi-Goutieres syndrome. Neuropediatrics 1999;30(1):38-41. PMID 10222460
27: Ramesh V, Bernardi B, Stafa A, et al. Intracerebral large artery disease in Aicardi-Goutieres syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol 2010;52(8):725-32. PMID 20653736
28: Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutieres syndrome--report of two sisters. Neuropediatrics 2005;36(1):40-4. PMID 15776321
29: Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007;1(4):713-25. PMID 17846997
30: Rice GI, Del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014;46(5):503-9. PMID 24686847
31: Rice GI, Meyzer C, Bouazza N, et al. Reverse-transcriptase inhibitors in the Aicardi-Goutieres syndrome. N Engl J Med 2018;379(23):2275-7. PMID 30566312
32: Song B, Shiromoto Y, Minakuchi M, Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip Rev RNA 2022;13(1):e1665. PMID 34105255
33: Swenson Schalkwyk AK, Agarwal R. Anesthesia for a patient with Aicardi-Goutieres syndrome: a first case report. A A Pract 2021;15(3):e01410. PMID 33684075
34: Tolmie JL, Shillito P, Hughes-Benzie R, Stephenson JB. The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet 1995;32(11):881-4. PMID 8592332
35: Troost D, van Rossum A, Veiga Pires J, Willemse J. Cerebral calcifications and cerebellar hypoplasia in two children: clinical, radiologic and neuropathological studies--a separate neurodevelopmental entity. Neuropediatrics 1984;15(2):102-9. PMID 6738816
36: Uggenti C, Lepelley A, Depp M, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet 2020;52(12):1364-72. PMID 33230297
37: Vanderver A, Adang L, Gavazzi F, et al. Janus kinase inhibition in the Aicardi-Goutieres syndrome. N Engl J Med 2020;383(10):986-9. PMID 32877590
38: Wu CC, Shinn-Forng Peng S, Lee WT. Intracerebral large artery disease in Aicardi-Goutieres syndrome with TREX1 mutation: a case report. Neurol Sci 2020;41(11):3353-6. PMID 32524323

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Kapil Arya MD

Dr. Arya of Arkansas Children's Hospital/UAMS has no relevant financial relationships to disclose.
See Profile
Ezgi Saylam MD

Dr. Saylam University of Nationwide Children's Hospital in Columbus, Ohio has no relevant financial relationships to disclose.
See Profile

Editor

Ganeshwaran H Mochida MD

Dr. Mochida of Boston Children's Hospital and Harvard Medical School has no relevant financial relationships to disclose.
See Profile

Former Authors

Francoise Goutieres MD
Pierre B Fayad MD
Marie-Laure Moutard MD
Isabelle Desguerre MD
Goknur Haliloglu MD
Haluk Topaloglu MD
Peter G Barth MD PhD
Joseph R Siebert PhD
Pierre Lebon MD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: male=female
Heredity: heredity may be a factor

heredity typical

autosomal recessive

autosomal dominant
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Leukodystrophy: 330.0
ICD-10: Other specified degenerative diseases of nervous system: G31.8
OMIM: Aicardi-Goutieres syndrome 1, AGS1: #225750

Aicardi-Goutieres syndrome 2, AGS2: #610181

Aicardi-Goutieres syndrome 3, AGS3: #610329

Aicardi-Goutieres syndrome 4, AGS4: #610333

Aicardi-Goutieres syndrome 5, AGS5: #612952

Aicardi-Goutieres syndrome 6, AGS6: #615010

Aicardi-Goutieres syndrome 7, AGS7: #615846

Aicardi-Goutieres syndrome 8, AGS8: #619486

Aicardi-Goutieres syndrome 9, AGS9: #619487

Basal ganglia calcification, idiopathic, childhood-onset: %114100

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Aicardi-Goutieres syndrome

Differential Diagnosis

TORCH infections
band-like calcification polymicrogyria
MICS (microcephaly, intracranial calcification syndrome, pseudo-TORCH syndrome)
mitochondrial cytopathies
endocrine diseases
- Cockayne syndrome and other leukodystrophies
- neonatal lupus erythematosus
- 3-hydroxyisobutyric aciduria
- leukoencephalopathy, brain calcifications, and cysts (Labrune syndrome)
- cerebroretinal microangiopathy with calcifications and cysts

Also Relevant

Common retinopathies
Congenital rubella
Cortical blindness
Idiopathic basal ganglia calcification
Intellectual disability
- Leukodystrophies
- Spasticity

Aicardi-Goutieres syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Clinical phenotypes

Table 1. Summary of Clinical Manifestations in Aicardi-Goutieres Syndrome

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

X-linked hydrocephalus (L1 syndrome)

Carnitine palmitoyltransferase II deficiency

Cerebro-oculo-facio-skeletal syndrome

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Schizencephaly

This is an article preview.
Start a Free Account
to access the full version.